Genmab Shares Fall After Net Income Misses Forecast

Dow Jones05-08

By Julia Fadi Nasser

Genmab shares fell after the Danish biotechnology company reported a fall in net profit that missed market forecasts.

Shares were down 7.3% to 1,630 Danish kroner in midafternoon European trading, leading the Stoxx 600 fallers. They are currently down 20% over the year to date.

The antibody company late Thursday reported a net profit for the first quarter ended March 31 of $53 million compared with $195 million for the comparable period a year earlier.

The fall was partly related to $45 million for acquisition and integration costs related to the Merus deal that completed on Dec. 12. Higher taxes also contributed in the fall.

Jefferies analysts had expected a net profit of $66 million for the quarter.

"We made tangible progress in the first quarter as we continue to integrate Merus and advance our late-stage portfolio," Chief Executive Jan van de Winkel said.

Despite the lower first quarter profit the company maintained its forecast for the year, as guided in February.

It expects to report revenue for the year of $4.065 billion to $4.395 billion and operating profit of $900 million to $1.40 billion.

Revenue for 2025 was $3.72 billion, and came in at $896 million for the first quarter of this year.

Operating profit for the year was $1.065 billion and $180 million for the first quarter.

Write to Julia Fadi Nasser at julia.nasser@wsj.com

(END) Dow Jones Newswires

May 08, 2026 09:01 ET (13:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633451531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633451531","market":"hk","top_or_hot":-1,"title":"Genmab Shares Fall After Net Income Misses Forecast","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Julia Fadi Nasser \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Genmab shares fell after the Danish biotechnology company reported a fall in net profit that missed market forecasts. \n</p>\n<p>\n  Shares were down 7.3% to  1,630 Danish kroner in midafternoon European trading, leading the Stoxx 600 fallers. They are currently down 20% over the year to date. \n</p>\n<p>\n  The antibody company late Thursday reported a net profit for the first quarter ended March 31 of $53 million compared with $195 million for the comparable period a year earlier. \n</p>\n<p>\n  The fall was partly related to $45 million for acquisition and integration costs related to the Merus deal that completed on Dec. 12. Higher taxes also contributed in the fall. \n</p>\n<p>\n  Jefferies analysts had expected a net profit of $66 million for the quarter. \n</p>\n<p>\n  \"We made tangible progress in the first quarter as we continue to integrate Merus and advance our late-stage portfolio,\" Chief Executive Jan van de Winkel said. \n</p>\n<p>\n  Despite the lower first quarter profit the company maintained its forecast for the year, as guided in February. \n</p>\n<p>\n  It expects to report revenue for the year of $4.065 billion to $4.395 billion and operating profit of $900 million to $1.40 billion. \n</p>\n<p>\n  Revenue for 2025 was $3.72 billion, and came in at $896 million for the first quarter of this year. \n</p>\n<p>\n  Operating profit for the year was $1.065 billion and $180 million for the first quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Julia Fadi Nasser at julia.nasser@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 09:01 ET (13:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genmab Shares Fall After Net Income Misses Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenmab Shares Fall After Net Income Misses Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-08 21:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Julia Fadi Nasser \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Genmab shares fell after the Danish biotechnology company reported a fall in net profit that missed market forecasts. \n</p>\n<p>\n  Shares were down 7.3% to  1,630 Danish kroner in midafternoon European trading, leading the Stoxx 600 fallers. They are currently down 20% over the year to date. \n</p>\n<p>\n  The antibody company late Thursday reported a net profit for the first quarter ended March 31 of $53 million compared with $195 million for the comparable period a year earlier. \n</p>\n<p>\n  The fall was partly related to $45 million for acquisition and integration costs related to the Merus deal that completed on Dec. 12. Higher taxes also contributed in the fall. \n</p>\n<p>\n  Jefferies analysts had expected a net profit of $66 million for the quarter. \n</p>\n<p>\n  \"We made tangible progress in the first quarter as we continue to integrate Merus and advance our late-stage portfolio,\" Chief Executive Jan van de Winkel said. \n</p>\n<p>\n  Despite the lower first quarter profit the company maintained its forecast for the year, as guided in February. \n</p>\n<p>\n  It expects to report revenue for the year of $4.065 billion to $4.395 billion and operating profit of $900 million to $1.40 billion. \n</p>\n<p>\n  Revenue for 2025 was $3.72 billion, and came in at $896 million for the first quarter of this year. \n</p>\n<p>\n  Operating profit for the year was $1.065 billion and $180 million for the first quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Julia Fadi Nasser at julia.nasser@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 09:01 ET (13:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GMAB","symbol_name":"Genmab A/S","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2633451531","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633451531","pubTimestamp":1778245260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Genmab shares fell after the Danish biotechnology company reported a fall in net profit that missed market forecasts.Shares were down 7.3% to  1,630 Danish kroner in midafternoon European trading, leading the Stoxx 600 fallers. They are currently down 20% over the year to date.The antibody company late Thursday reported a net profit for the first quarter ended March 31 of $53 million compared with $195 million for the comparable period a year earlier.The fall was partly related to $45 million for acquisition and integration costs related to the Merus deal that completed on Dec. 12. Higher taxes also contributed in the fall.Jefferies analysts had expected a net profit of $66 million for the quarter.\"We made tangible progress in the first quarter as we continue to integrate Merus and advance our late-stage portfolio,\" Chief Executive Jan van de Winkel said.Despite the lower first quarter profit the company maintained its forecast for the year, as guided in February.Revenue for 2025 was $","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GMAB":"Genmab A/S","BK4139":"生物科技"},"translate_title":"净利润未达预期后Genmab股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":0.9},"content_text":"By Julia Fadi Nasser \n\n\n \n\n\n  Genmab shares fell after the Danish biotechnology company reported a fall in net profit that missed market forecasts. \n\n\n  Shares were down 7.3% to  1,630 Danish kroner in midafternoon European trading, leading the Stoxx 600 fallers. They are currently down 20% over the year to date. \n\n\n  The antibody company late Thursday reported a net profit for the first quarter ended March 31 of $53 million compared with $195 million for the comparable period a year earlier. \n\n\n  The fall was partly related to $45 million for acquisition and integration costs related to the Merus deal that completed on Dec. 12. Higher taxes also contributed in the fall. \n\n\n  Jefferies analysts had expected a net profit of $66 million for the quarter. \n\n\n  \"We made tangible progress in the first quarter as we continue to integrate Merus and advance our late-stage portfolio,\" Chief Executive Jan van de Winkel said. \n\n\n  Despite the lower first quarter profit the company maintained its forecast for the year, as guided in February. \n\n\n  It expects to report revenue for the year of $4.065 billion to $4.395 billion and operating profit of $900 million to $1.40 billion. \n\n\n  Revenue for 2025 was $3.72 billion, and came in at $896 million for the first quarter of this year. \n\n\n  Operating profit for the year was $1.065 billion and $180 million for the first quarter. \n\n\n \n\n\n  Write to Julia Fadi Nasser at julia.nasser@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 09:01 ET (13:01 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633451531","isCrawlerRequest":true}